AlloDerm Vs DermACELL in Breast Reconstruction: A Systematic Review and Meta-Analysis of All Head-to-Head Comparisons

AlloDerm (LifeCell, Branchburg, NJ) and DermACELL (LifeNet Health, Virginia Beach, VA) are 2 commonly used acellular dermal matrices (ADMs) in aesthetic and reconstructive breast surgery.

In this head-to-head meta-analysis, the authors aim to compare the clinical outcomes, including complication rates and BREAST-Q patient satisfaction, associated with AlloDerm and DermACELL.

PubMed, Scopus, and Web of Science were searched for relevant studies in April 2024 and again in April 2025. The authors included all studies with data comparing AlloDerm and DermACELL. Statistical analyses were performed using RevMan 5.4. Heterogeneity was assessed using I ² statistics. A random-effects model was applied in case of significant heterogeneity followed by sensitivity analysis.

The search yielded 1006 studies, of which 14 were included in the meta-analysis. A total of 1872 patients (2940 breasts) were analyzed, with 1724 breasts receiving AlloDerm and 1433 breasts receiving DermACELL. The analysis revealed that AlloDerm was associated with a slightly higher incidence of seroma formation (risk ratio = 1.49, 95% CI, 1.14-1.95, P = .003) compared with DermACELL, which may be because of surgical technique rather than ADM. No significant differences were observed in the rates of all other complications and BREAST-Q outcomes. Further, there was no statistically significant difference in the rate of red breast syndrome after sensitivity analysis.

DermACELL demonstrated a slightly lower incidence of seroma formation compared with AlloDerm. Further randomized trials are needed to confirm these results and explore the long-term outcomes associated with both ADMs.